<unk>  (INN; brand name Xadago) is a drug used as an add-on treatment for Parkinson's disease with "off" episodes; it has multiple modes of action, including the inhibition of monoamine oxidase B. It was approved in Europe in February 2015, in the United States in March 2017, and in Canada in January 2019.
Safinamide
Pyrazinamide
Ethambutol
Isoniazid
Oxepanoprolinamide
Rifampicin
Plazomicin
Rifabutin